United Guardian's Q3 Profit Plunges 69% Amid China Tariff Headwinds

TL;DR

**UG's Q3 results are a disaster, with profits down nearly 70% due to China tariffs and product delays – sell now.**

AI Summary

UNITED GUARDIAN INC (UG) reported a significant decline in financial performance for the three and nine months ended September 30, 2025. Net sales for the three months decreased by 26.0% to $2,264,261 from $3,060,113 in the prior year, and for the nine months, net sales fell by 21.9% to $7,583,613 from $9,705,262. This revenue decline directly impacted net income, which plummeted by 69.0% to $268,441 for the three-month period from $865,484, and by 47.0% to $1,456,162 for the nine-month period from $2,747,151. Earnings per common share also decreased substantially, from $0.19 to $0.06 for the quarter and from $0.60 to $0.32 for the nine months. The company cited softened demand in China due to tariffs as a key factor affecting cosmetic product sales. Strategic outlook includes delayed manufacturing of the new Natrajel line until 2026, impacting expected sales in 2025. Cash and cash equivalents decreased from $1,875,655 at December 31, 2024, to $860,836 at September 30, 2025.

Why It Matters

This significant decline in revenue and net income for UNITED GUARDIAN INC signals a challenging period, particularly for investors who rely on consistent earnings and dividends. The delay in the Natrajel product launch to 2026, initially expected in 2025, could further impact future growth prospects and investor confidence. For employees, sustained revenue pressure might lead to cost-cutting measures. Customers, especially those in China, are experiencing price increases due to tariffs, potentially shifting demand to competitors. In the broader market, this highlights the tangible impact of U.S.-China trade tensions on specialized chemical and pharmaceutical companies, potentially affecting other firms with similar international exposure.

Risk Assessment

Risk Level: high — The company experienced a 69.0% decrease in net income for the three months ended September 30, 2025, falling to $268,441 from $865,484 in the prior year, and a 47.0% decrease for the nine months. This substantial decline is directly attributed to a 26.0% drop in net sales for the quarter and a 21.9% drop for the nine months, largely due to 'softened demand in China due to these tariffs' on cosmetic products, indicating significant exposure to geopolitical trade risks.

Analyst Insight

Investors should consider reducing their exposure to UG given the substantial decline in net income and sales, coupled with the delayed Natrajel product launch. Monitor ongoing U.S.-China trade negotiations closely, as further negative developments could exacerbate the company's financial challenges. Re-evaluate the company's long-term growth potential in light of these persistent headwinds.

Financial Highlights

debt To Equity

N/A

revenue

$7,583,613

operating Margin

20.1%

total Assets

$12,180,345

total Debt

$1,597,909

net Income

$1,456,162

eps

$0.32

gross Margin

43.0%

cash Position

$860,836

revenue Growth

-21.9%

Revenue Breakdown

Key Numbers

• $2,264,261 — Net sales for Q3 2025 (26.0% decrease from $3,060,113 in Q3 2024)
• $7,583,613 — Net sales for nine months 2025 (21.9% decrease from $9,705,262 in nine months 2024)
• $268,441 — Net income for Q3 2025 (69.0% decrease from $865,484 in Q3 2024)
• $1,456,162 — Net income for nine months 2025 (47.0% decrease from $2,747,151 in nine months 2024)
• $0.06 — Earnings per common share for Q3 2025 (Decreased from $0.19 in Q3 2024)
• $0.32 — Earnings per common share for nine months 2025 (Decreased from $0.60 in nine months 2024)
• $860,836 — Cash and cash equivalents at September 30, 2025 (Decreased from $1,875,655 at December 31, 2024)
• 10% — Retaliatory tariff rate by China (Maintained until November 10, 2025)
• 2026 — Expected manufacturing start for Natrajel (Delayed from 2025)
• $2,766,720 — Dividends paid for nine months 2025 (Slight increase from $2,756,323 in nine months 2024 despite lower income)

Key Players & Entities

• UNITED GUARDIAN INC (company) — Registrant
• Guardian Laboratories (company) — division of United Guardian, Inc.
• Brenntag Specialties (company) — global market leader in chemicals and ingredients distribution
• Natrajel (product) — new line of sexual wellness ingredients
• Renacidin (product) — urological irrigation solution, pharmaceutical product
• U.S. Securities and Exchange Commission (regulator) — filing recipient
• NASDAQ Global Market (market) — exchange where UG common stock is registered
• Centers for Medicare & Medicaid Services (regulator) — implemented new Medicare Part D Manufacturer Discount Program
• President (person) — chief operating decision maker (CODM)
• Board of Directors (company) — evaluates financial metrics with CODM

FAQ

Risk Factors

• China Tariffs Impacting Cosmetic Sales [high — market]: The company cited softened demand in China due to tariffs as a key factor affecting cosmetic product sales. This resulted in a 21.9% decrease in net sales for the nine months ended September 30, 2025, compared to the prior year.
• Natrajel Product Launch Delay [medium — operational]: Manufacturing of the new Natrajel line has been delayed until 2026 due to customer launch timelines. This delay is expected to impact sales in 2025, which were anticipated to begin in the current year.
• Dependence on Key Distribution Agreements [medium — market]: The company relies on distribution agreements, such as the one with Brenntag Specialties for the Natrajel line. Any disruption or underperformance in these agreements could negatively affect sales and market penetration.
• Declining Cash Position [high — financial]: Cash and cash equivalents decreased significantly from $1,875,655 at December 31, 2024, to $860,836 at September 30, 2025. This reduction in liquidity could impact the company's ability to fund operations or invest in growth.
• Decreased Profitability [high — financial]: Net income for the nine months ended September 30, 2025, fell by 47.0% to $1,456,162 from $2,747,151 in the prior year. Earnings per common share also dropped from $0.60 to $0.32.
• Reliance on Hauppauge Manufacturing Facility [medium — operational]: All products, except Renacidin, are produced at the Hauppauge, New York facility. Any operational disruptions at this single location could significantly impact production and supply chain.
• Competition in Specialty Ingredients [medium — market]: The company operates in competitive markets for specialty cosmetic ingredients, pharmaceutical products, and medical lubricants. Maintaining market share and developing innovative products is crucial.

Industry Context

United-Guardian operates in the specialty chemicals sector, focusing on cosmetic ingredients, pharmaceutical products, and medical lubricants. The cosmetic ingredients market is influenced by consumer trends, demand in key international markets like China, and the development of natural and environmentally friendly raw materials. The sexual wellness ingredient market is a growing segment, but subject to product development timelines and distribution partnerships.

Regulatory Implications

The company is subject to standard regulations for chemical manufacturing and product safety in the cosmetic, pharmaceutical, and medical device sectors. Tariffs imposed by countries like China represent a significant regulatory and trade-related risk that directly impacts international sales and profitability.

What Investors Should Do

1. Monitor China Market Dynamics
2. Assess Natrajel Launch Progress
3. Evaluate Cash Burn and Liquidity
4. Analyze Cost Management Strategies

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant declines in net sales and net income, with cash and cash equivalents down substantially from year-end 2024.
• 2026-01-01: Expected start of Natrajel manufacturing — Delayed from 2025, this impacts expected sales for the new sexual wellness product line.
• 2025-11-10: Tariff rate by China maintained until this date — The 10% retaliatory tariff rate has been a factor in softened demand for cosmetic products in China.
• 2024-12-31: End of Fiscal Year 2024 — Company had $1,875,655 in cash and cash equivalents and $9,705,262 in net sales for the nine months of 2024.

Glossary

Lubrajel hydrogels

A line of hydrogel ingredients manufactured by United-Guardian, Inc., used in cosmetic and pharmaceutical products. (Core product line contributing to the company's revenue.)

Natrajel

A new line of sexual wellness ingredients developed by United-Guardian, Inc. (Its delayed launch until 2026 is a key factor impacting current financial performance expectations.)

Renacidin

A urological irrigation solution manufactured for United-Guardian, Inc. by an outside contract manufacturer. (An exception to the company's in-house manufacturing model.)

Gross Margin

The difference between revenue and cost of goods sold, expressed as a percentage of revenue. (Indicates the profitability of the company's core product sales before operating expenses.)

Operating Margin

Profitability from core business operations, calculated as income from operations divided by net sales. (Measures the efficiency of the company's operations.)

Weighted average shares (Basic and Diluted)

The average number of outstanding shares of common stock over a period, used for calculating earnings per share. (Used to calculate EPS, which has seen a significant decrease.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, United-Guardian Inc. has experienced a significant downturn. Net sales decreased by 21.9% to $7,583,613, directly impacting net income, which plummeted by 47.0% to $1,456,162. Earnings per share also halved from $0.60 to $0.32. A key new risk factor highlighted is the impact of tariffs on China's cosmetic market, alongside the operational risk of a delayed product launch for the Natrajel line. The company's cash position has also weakened considerably, falling from $1,875,655 at the end of 2024 to $860,836 by September 30, 2025.

Key Financial Figures

• $0.10 — nge on which registered Common Stock, $0.10 par value per share UG NASDAQ Globa
• $250,000 — insured by the FDIC up to a maximum of $250,000. At September 30, 2025 and December 31,

Filing Documents

• ug20250930_10q.htm (10-Q) — 699KB
• ex_879938.htm (EX-31.1) — 13KB
• ex_879939.htm (EX-31.2) — 13KB
• ex_879940.htm (EX-32) — 8KB
• 0001171843-25-007077.txt ( ) — 4021KB
• ug-20250930.xsd (EX-101.SCH) — 44KB
• ug-20250930_def.xml (EX-101.DEF) — 279KB
• ug-20250930_lab.xml (EX-101.LAB) — 217KB
• ug-20250930_pre.xml (EX-101.PRE) — 306KB
• ug-20250930_cal.xml (EX-101.CAL) — 38KB
• ug20250930_10q_htm.xml (XML) — 525KB

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION

- Condensed Financial Statements (unaudited unless indicated otherwise)

Item 1 - Condensed Financial Statements (unaudited unless indicated otherwise) 2 2 Balance Sheets – September 30, 2025 (unaudited) and December 31, 2024 (audited) 3 - 4 5 6 Notes to Condensed Financial Statements 7 - 19

- Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 19 - 24

- Quantitative and Qualitative Disclosures About Market Risk

Item 3 - Quantitative and Qualitative Disclosures About Market Risk 24

- Controls and Procedures

Item 4 - Controls and Procedures 24 - 25

OTHER INFORMATION

Part II. OTHER INFORMATION

- Legal Proceedings

Item 1 - Legal Proceedings 25

- Risk Factors

Item 1A - Risk Factors 25 - 26

- Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 26

- Defaults Upon Senior Securities

Item 3 - Defaults Upon Senior Securities 26

- Mine Safety Disclosures

Item 4 - Mine Safety Disclosures 26

- Other Information

Item 5 - Other Information 27

- Exhibits

Item 6 - Exhibits 27

Signatures

Signatures 28 Page 1 of 28 UNITED-GUARDIAN, INC.

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION

Condensed Financial Statements

ITEM 1. Condensed Financial Statements (UNAUDITED) THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30, 2025 2024 2025 2024 Net sales $ 2,264,261 $ 3,060,113 $ 7,583,613 $ 9,705,262 Costs and expenses: Cost of sales 1,311,192 1,408,866 3,775,122 4,526,446 Operating expenses 620,893 591,047 1,947,678 1,762,689 Research and development expense 117,104 111,072 339,366 325,714 Total costs and expenses 2,049,189 2,110,985 6,062,166 6,614,849 Income from operations 215,072 949,128 1,521,447 3,090,413 Other Income: Investment income 75,165 99,934 230,425 298,014 Net gain on marketable securities 36,238 47,223 73,164 79,218 Total other income 111,403 147,157 303,589 377,232 Income before provision for income taxes 326,475 1,096,285 1,825,036 3,467,645 Provision for income taxes 58,034 230,801 368,874 720,494 Net income $ 268,441 $ 865,484 $ 1,456,162 $ 2,747,151 Earnings per common share (Basic and Diluted) $ 0.06 $ 0.19 $ 0.32 $ 0.60 Weighted average shares (Basic and Diluted) 4,594,319 4,594,319 4,594,319 4,594,319 See Notes to Condensed Financial Statements Page 2 of 28 UNITED-GUARDIAN, INC. BALANCE SHEETS ASSETS SEPTEMBER 30, DECEMBER 31, 2025 2024 (UNAUDITED) (AUDITED) Current assets: Cash and cash equivalents $ 860,836 $ 1,875,655 Marketable securities 7,443,756 7,522,625 Accounts receivable, net of allowance for credit losses of $ 14,092 at September 30, 2025 and $ 14,342 at December 31, 2024 1,161,703 1,428,455 Inventories, net 1,408,703 1,451,995 Prepaid expenses and other current assets 153,669 207,804 Prepaid income taxes 218,226 179,017 Total current assets 11,246,893 12,665,551 Deferred income taxes (net) 18,094 175,397 Net property, plant, and equipment: Land 69,000 69,000 Factory equipmen

Business

Business United-Guardian, Inc. ("Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic ingredients, notably a line of Lubrajel hydrogels, pharmaceutical products, medical lubricants and sexual wellness ingredients. In October 2023, the Company entered into a distribution agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for the distribution of the Company's new Natrajel line of sexual wellness ingredients in the United States, Canada, Mexico, Central America and South America. We had expected to begin manufacturing and reporting sales of this new line of products in 2025, but manufacturing has been delayed until 2026 due to customer launch timeline. The Company conducts various Research and Development ("R&D") activities. Our R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We also develop new medical lubricants for our medical customers. The Company develops new products using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. Our R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets that our products are used in. All the products that we market, except for Renacidin , are produced at our facility in Hauppauge, New York. Renacidin, a urological irrigation solution, is manufactured for us by an outside contract manufacturer. 2. Basis of Presentation Interim condensed financial statements of the Company are prepared in accordance with generally accepted accounting principles in the United States of America ("US GAAP") for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements f

View Full Filing

View this 10-Q filing on SEC EDGAR